Skip to main navigation Skip to search Skip to main content

A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients

Project: Research

Project Details

StatusFinished
Effective start/end date10/19/22 → 02/1/26

Funding

  • ICON Clinical Research: $33,945.00